Get the Stockscreener App
207.51
1.42%
2.90
After Hours:
207.51
Icon Plc stock is traded at $207.51, with a volume of 786.84K.
It is up +1.42% in the last 24 hours and up +1.89% over the past month.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
See More
Previous Close:
$204.61
Open:
$200.88
24h Volume:
786.84K
Relative Volume:
0.62
Market Cap:
$17.13B
Revenue:
$8.31B
Net Income/Loss:
$747.89M
P/E Ratio:
33.47
EPS:
6.2
Net Cash Flow:
$1.23B
1W Performance:
-0.31%
1M Performance:
+1.89%
6M Performance:
-34.33%
1Y Performance:
-25.73%
1-Day Range:
$200.69
$210.05
1-Week Range:
$200.69
$211.76
52-Week Range:
$183.38
$347.72
Icon Plc Stock (ICLR) Company Profile
Compare ICLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
207.51 | 17.13B | 8.31B | 747.89M | 1.23B | 8.97 |
|
TMO
Thermo Fisher Scientific Inc
|
524.05 | 200.45B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
228.55 | 165.08B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
134.51 | 38.36B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.27 | 35.80B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
412.26 | 33.76B | 3.84B | 866.24M | 792.60M | 10.37 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
Bioanalytical Services Market Key Players AnalysisPPD, Inc., - openPR
ICON plc Appoints Barry Balfe as Chief Operating Officer - TipRanks
ICON plc appoints Barry Balfe as new COO - Investing.com
ICON Appoints 20-Year Veteran Barry Balfe as Chief Operating Officer to Drive Strategic Growth - StockTitan
ICON's SWOT analysis: CRO giant navigates turbulent market - Investing.com
ICON plc Announces Appointment of Barry Balfe as Chief Operating Officer - Marketscreener.com
October 2025 Options Now Available For Icon - Nasdaq
Contract Research Organization Services Market Set to Witness Significant Growth by 2024-2031: IQVIA, LabCorp, - EIN News
ICON's SWOT analysis: cro stock navigates challenges amid industry shifts - Investing.com
Preclinical Assets Market CAGR of 7.5% Size, Share, Trends, Future Prospect By 2024-2031 | Eurofins - EIN News
Biomarker Research Services Market Set to Witness Significant Growth by 2024-2031:Reprocell Corporation, - EIN News
ICON Public Limited Company (ICLR) Fell on Reduced Guidance - Insider Monkey
Virtual Clinical Trials Market Key Players AnalysisICON, plc; Parexel International Corporation; IQVIA; Covance. - openPR
ICON Survey Highlights Sustained Investment in AI and Digital R&D Innovation, Tempered by Siloed Adoption - sharewise
ICON Survey: 82% of Pharma Leaders See AI Boosting R&D Returns as Digital Investment Surges 34% - StockTitan
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors - GlobeNewswire Inc.
Top 30 IQVIA Competitors & Alternatives in [year] - Marketing91
Icon PLC (ICLR) Down 4.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Should You Retain Your Conviction in Icon Plc (ICLR)? - Yahoo Finance
ICON stock labeled a "Fresh Pick" as Baird bets on recovery at current valuation - Investing.com
Pharmacovigilance and Drug Safety Software Market Skyrockets to $359.30 Million by 2031 Dominated by Tech GiantsArisEurope, ICON plc and Syneos Health | The Insight Partners - GlobeNewswire
Redburn Atlantic Initiates Coverage of ICON Public Limited (ICLR) with Neutral Recommendation - MSN
ICON Public Limited (NASDAQ:ICLR) Shares Sold by Entropy Technologies LP - MarketBeat
Prudential expands preferred healthcare network in partnership with Icon Cancer Centre - Media OutReach
ICON Plc stock hits 52-week low at $208.38 amid market shifts - Investing.com India
ICON to Present at London Healthcare Conference - TipRanks
ICON plc to Present at the Jefferies London Healthcare Conference - Business Wire
Icon Plc (ICLR-Q) QuotePress Release - The Globe and Mail
Rose Kidd, ICON – Winner of WMB Businesswoman Award 2024 - Women Mean Business
Icon PLC (ICLR) Shares Up 3.48% on Nov 6 - GuruFocus.com
Life Sciences BPO Market Set to Witness Significant Growth by 2024-2031:Catalent, Inc., Covance, Inc., Fareva, - EIN News
Contract Research Organization Services Market Business - openPR
Icon (FRA:IJF) GF Value Rank : 10 (As of Nov. 04, 2024) - GuruFocus.com
ICON Plc stock touches 52-week low at $219.87 amid market shifts - Investing.com Australia
Icon PLC (ICLR) Trading 3.72% Higher on Oct 2 - GuruFocus.com
ICLR Misses on Q3 Earnings, Lowers 2024 Guidance, Stock Falls - Yahoo Finance
ICON's $650 Million Power Play: Can This Bold Move Reverse a 21% Stock Plunge? - Yahoo Finance UK
ICON perks up after $250M share buyback - MSN
Baird Downgrades ICON Public Limited (ICLR) - MSN
Icon plc Strengthens Investor Confidence with Secured Notes - TipRanks
Earnings call: ICON PLC faces headwinds, eyes strategic growth By Investing.com - Investing.com Australia
Earnings call: ICON PLC faces headwinds, eyes strategic growth - Investing.com India
Icon Earnings: Shares Tank as Elevated Cancellations Reduce 2024 Guidance - Morningstar
Icon PLC (ICLR) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
ICON Public Limited Company (NASDAQ:ICLR) Q3 2024 Earnings Call Transcript - Insider Monkey
Pharmaceutical Contract Sales Outsourcing (CSO) Market Projected To Witness Substantial Growth, 2024-2031: - EIN News
Icon PLC (ICLR) Q3 2024 Earnings Call Highlights: Navigating Cha - GuruFocus.com
ICON Plc stock touches 52-week low at $227.56 amid market shifts - Investing.com Australia
U.S. Markets Finished Mixed Thursday As Tesla Led, Icon PLC Lagged - Barron's
ICON stock slips after guidance cut (ICLR:NASDAQ) - Seeking Alpha
Icon PLC Down Over 19%, on Pace for Largest Percent Decrease Since March 1999 — Data Talk - Morningstar
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):